A 58-year-old woman from Bangalore is diagnosed with Stage IIB serous epithelial ovarian cancer after exploratory laparotomy. She has no residual disease after optimal cytoreduction. Molecular testing reveals she is BRCA1 wild-type, and her tumor shows low homologous recombination deficiency (HRD) score. She receives 6 cycles of carboplatin–paclitaxel chemotherapy and achieves complete clinical response. CA-125 normalizes to <10 U/mL. Which of the following is the most appropriate maintenance therapy strategy for this patient?